En esta página
PHAT Phathom Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Jul 30, 2026
$6,92
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$6,82mínimo 52 semanas
$18,31máximo 52 semanas
Capitalización Bursátil (MRQ)
$554M
P/E (TTM)
-5.5
BPA (TTM)
$-1.25
Ingresos (TTM)
$240M
tus insignias
Rango 52S
$7–$18
Calificación del Analista
BUY
Precio Objetivo
$20
P/E
-5.5
ROE
26.4%
Margen de Beneficio Neto
-41.3%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
PHAT Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$6.92
Capitalización Bursátil (MRQ)
$554M
P/E (TTM)
-5.5
BPA (TTM)
$-1.25
Ingresos (TTM)
$240M
ROE (TTM)
26.4%
Deuda/Capital (MRQ)
-0.5
Rango 52S
$7–$18
PHAT Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$175M2022-12-31 → 2025-12-31
BPA$-3.032021-12-31 → 2025-12-31
Flujo de caja libre$-167M2019-12-31 → 2025-12-31
Margen neto-41.3%2023-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | PHAT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -5.5promedio 5A ≈-3.3 | ≈-3.3 | · | · | |
| P/S (TTM) | 2.3promedio 5A ≈263.8 | ≈263.8 | 2.7 | Más caro | |
| P/C (MRQ) | -1.6promedio 5A ≈-1.9 | ≈-1.9 | · | · | |
| EV / EBITDA | -3.9promedio 5A ≈-3.4 | ≈-3.4 | · | · | |
| Precio / FCF (TTM) | -15.0promedio 5A ≈-4.0 | ≈-4.0 | · | · | |
| Precio / Flujo de Caja (TTM) | -15.1promedio 5A ≈-4.0 | ≈-4.0 | · | · | |
| EV / Revenue (EV / Ingresos) | 3.6promedio 5A ≈144.3 | ≈144.3 | · | · | |
| EV / FCF | -3.8promedio 5A ≈-3.4 | ≈-3.4 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | PHAT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Bruto (TTM) | 82.9%promedio 5A ≈82.7% | ≈82.7% | 71.8% | De primer nivel | |
| Margen Operativo (TTM) | -17.0%promedio 5A ≈-8375.4% | ≈-8375.4% | -1.8% | Por debajo del promedio | |
| Margen EBITDA (TTM) | -16.7%promedio 5A ≈-8346.7% | ≈-8346.7% | 1.8% | Débil | |
| Pretax Margin (Margen antes de impuestos) | -126.4% | · | -6.8% | Débil | |
| Margen de Beneficio Neto (TTM) | -41.3%promedio 5A ≈-10096.8% | ≈-10096.8% | -7.5% | Débil | |
| ROA (TTM) | -34.3%promedio 5A ≈-78.9% | ≈-78.9% | -15.7% | Débil | |
| ROE (TTM) | 26.4%promedio 5A ≈175.3% | ≈175.3% | 52.3% | En línea | |
| ROIC | 69.8% | · | 40.3% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | PHAT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | -0.5promedio 5A ≈-0.6 | ≈-0.6 | 0.0 | Baja deuda | |
| Ratio corriente (MRQ) | 1.9promedio 5A ≈6.4 | ≈6.4 | 3.0 | Baja liquidez | |
| Quick Ratio (Ratio Rápido) | 1.6promedio 5A ≈6.2 | ≈6.2 | 2.0 | En línea | |
| Deuda a Largo Plazo / Patrimonio (MRQ) | -0.5promedio 5A ≈-0.6 | ≈-0.6 | 0.0 | Baja deuda |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | PHAT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 216.9% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | PHAT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.5promedio 5A ≈0.2 | ≈0.2 | 0.5 | De primer nivel | |
| Inventory Turnover (Rotación de Inventario) | 5.2promedio 5A ≈3.0 | ≈3.0 | 3.0 | De primer nivel | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 3.0promedio 5A ≈2.2 | ≈2.2 | 3.5 | Débil | |
| Revenue / Employee (Ingresos / Empleado) | ≈$472.0K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
7.7%
Próximo informe
Oct 28, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 5, 2026 | $-0.21 | $-0.26 | 18.1% |
| 31 de marzo de 2026 | May 12, 2026 | $-0.37 | $-0.33 | -12.6% |
| 31 de diciembre de 2025 | $-0.29 | $-0.39 | 25.5% | |
| 30 de septiembre de 2025 | $-0.41 | $-0.56 | 26.2% | |
| 30 de junio de 2025 | $-1.05 | $-1.06 | 1.0% | |
| 31 de marzo de 2025 | $-1.31 | $-1.17 | -12.0% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $175M | $55M | $682.0K | $0 | |
| Cost of Revenue | $23M | $8M | $167.0K | $0 | |
| Gross Profit | $153M | $47M | $515.0K | $0 | |
| R&D Expense | $33M | $34M | $50M | $71M | |
| SG&A Expense | $280M | $291M | $118M | $101M | |
| Operating Expenses | $312M | $325M | $168M | $172M | |
| Operating Income | $-160M | $-277M | $-167M | $-172M | |
| Interest Expense | · | · | $42M | $27M | |
| Interest Income | $7M | $15M | $8M | $2M | |
| Other Non-op | $-190.0K | $-8.0K | $-188.0K | $-110.0K | |
| Pretax Income | $-221M | $-334M | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-221M | $-334M | $-202M | $-198M | |
| EPS (Basic) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | |
| EPS (Diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | |
| Shares (Basic) | 72,918,764 | 63,176,210 | 51,289,092 | 39,118,215 | |
| Shares (Diluted) | 72,918,764 | 63,176,210 | 51,289,092 | 39,118,215 | |
| EBITDA | $-159M | $-277M | $-167M | $-172M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $130M | $297M | $381M | $155M | |
| Receivables | $78M | $39M | $2M | $0 | |
| Inventory | $6M | $3M | $1M | $0 | |
| Prepaid Expense | $15M | $21M | $13M | $5M | |
| Current Assets | $229M | $360M | $397M | $161M | |
| PP&E (Net) | $1M | $1M | $2M | $1M | |
| PP&E (Gross) | $5M | $4M | $4M | $3M | |
| Accum. Depreciation | $3M | $3M | $2M | $1M | |
| Other Non-current Assets | $3M | $2M | $2M | $299.0K | |
| Total Assets | $259M | $378M | $414M | $165M | |
| Accounts Payable | $5M | $11M | $13M | $10M | |
| Accrued Liabilities | $90M | $53M | $17M | $15M | |
| Current Liabilities | $132M | $86M | $39M | $26M | |
| Capital Leases | $2M | · | $462.0K | $1M | |
| Other Non-current Liabilities | $4M | $12M | $10M | $8M | |
| Total Liabilities | $697M | $632M | $487M | $240M | |
| Long-term Debt | $209M | $201M | $138M | $95M | |
| Total Debt | $209M | $201M | $138M | $95M | |
| Common Stock | $6.0K | $6.0K | $5.0K | $3.0K | |
| Retained Earnings | $-1.48B | $-1.26B | $-929M | $-727M | |
| Treasury Stock | $0 | $0 | $0 | $0 | |
| Stockholders' Equity | $-438M | $-254M | $-73M | $-75M | |
| Liabilities + Equity | $259M | $378M | $414M | $165M | |
| Shares Outstanding | 71,419,025 | 68,518,238 | 57,970,044 | 41,468,871 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| D&A | $633.0K | $795.0K | $575.0K | $620.0K | |
| Stock-based Comp | $29M | $24M | $45M | $24M | |
| Other Non-cash | $25M | $43M | $18M | $26M | |
| Operating Cash Flow | $-167M | $-267M | $-138M | $-147M | |
| CapEx | $229.0K | $135.0K | $2M | $1M | |
| Investing Cash Flow | $-229.0K | $-135.0K | $-2M | $-1M | |
| Debt Issued | $0 | $59M | $39M | $0 | |
| Net Debt Issued | $0 | $59M | $39M | · | |
| Stock Issued | · | · | $14M | · | |
| Financing Cash Flow | $-288.0K | $183M | $368M | $120M | |
| Net Change in Cash | $-167M | $-84M | $228M | $-28M | |
| Free Cash Flow | $-167M | $-267M | $-139M | $-148M |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Gross Margin | 87.1% | 85.6% | 75.5% | · | |
| Operating Margin | -91.4% | -502.2% | -24532.5% | · | |
| Net Margin | -126.4% | -605.1% | -29558.9% | · | |
| Pretax Margin | -126.4% | · | · | · | |
| EBITDA Margin | -91.0% | -500.8% | -24448.2% | · | |
| ROA | -69.4% | -84.4% | -69.7% | -111.6% | |
| ROE | 52.4% | 151.7% | 445.4% | 390.6% | |
| ROIC | 69.8% | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 1.7 | 4.2 | 10.2 | 6.1 | |
| Quick Ratio | 1.6 | 3.9 | 9.9 | 5.9 | |
| Debt / Equity | -0.5 | -0.8 | -1.9 | -1.3 | |
| LT Debt / Equity | -0.5 | -0.8 | -1.9 | -1.3 | |
| Interest Coverage | · | · | -4.0 | -6.3 |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.1 | 0.0 | · | |
| Inventory Turnover | 5.2 | 3.6 | 0.3 | · | |
| Receivables Turnover | 3.0 | 2.7 | 0.8 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $-6.14 | $-4.37 | $-1.26 | $-1.80 | |
| Revenue / Share | $2.40 | $0.87 | $0.01 | · | |
| Cash Flow / Share | $-2.29 | $-4.22 | $-2.68 | $-3.75 | |
| Cash / Share | $1.82 | $5.13 | $6.58 | $3.75 | |
| EPS (TTM) | $-3.03 | $-5.29 | $-3.93 | $-5.05 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | 216.9% | 8001.5% | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $175M | $55M | $682.0K | $0 | |
| Net Income TTM | $-221M | $-334M | $-202M | $-198M | |
| Market Cap | $1.18B | $471M | $529M | $465M | |
| Enterprise Value | $1.26B | $375M | $286M | $405M | |
| P/E | -5.5 | -1.5 | -2.3 | -2.2 | |
| P/S | 6.8 | 8.5 | 776.1 | · | |
| P/B | -2.7 | -1.9 | -7.3 | -6.2 | |
| P / Cash Flow | -7.1 | -1.8 | -3.8 | -3.2 | |
| P / FCF | -7.1 | -1.8 | -3.8 | -3.2 | |
| EV / EBITDA | -7.9 | -1.4 | -1.7 | -2.4 | |
| EV / FCF | -7.6 | -1.4 | -2.1 | -2.7 | |
| EV / Revenue | 7.2 | 6.8 | 418.9 | · | |
| Earnings Yield | -18.3% | -65.1% | -43.0% | -45.0% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74M | $58M | $58M | $50M | $40M | $29M | $30M | $16M | $7M | $2M | $682.0K | $0 | $0 | $0 | |
| Cost of Revenue | $15M | $12M | $8M | $6M | $5M | $4M | $4M | $2M | $1M | $426.0K | $167.0K | $0 | $0 | $0 | |
| Gross Profit | $59M | $46M | $50M | $43M | $34M | $25M | $26M | $14M | $6M | $1M | $515.0K | $0 | $0 | $0 | |
| R&D Expense | $8M | $8M | $7M | $7M | $9M | $9M | $9M | $9M | $7M | $9M | $13M | $12M | $13M | $11M | |
| SG&A Expense | $55M | $54M | $48M | $52M | $85M | $94M | $77M | $76M | $76M | $62M | $57M | $23M | $19M | $19M | |
| Operating Expenses | $63M | $62M | $56M | $59M | $94M | $104M | $85M | $85M | $83M | $71M | $70M | $36M | $32M | $30M | |
| Operating Income | $-4M | $-15M | $-6M | $-15M | $-60M | $-79M | $-59M | $-71M | $-77M | $-70M | $-70M | $-36M | $-32M | $-30M | |
| Interest Expense | · | · | · | · | · | · | · | · | $18M | $17M | · | $10M | $10M | $9M | |
| Interest Income | $2M | $2M | $1M | $1M | $2M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | $348.0K | $1M | |
| Other Non-op | $-24.0K | $-831.0K | $-6.0K | $-7.0K | $-155.0K | $-22.0K | $49.0K | $-8.0K | $-6.0K | $-43.0K | $-14.0K | $-197.0K | $3.0K | $20.0K | |
| Net Income | $-18M | $-30M | $-21M | $-30M | $-76M | $-94M | $-74M | $-86M | $-91M | $-83M | $-80M | $-43M | $-41M | $-38M | |
| EPS (Basic) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 | $-1.56 | $-1.42 | $-1.44 | $-0.76 | $-0.84 | $-0.89 | |
| EPS (Diluted) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 | $-1.56 | $-1.42 | $-1.44 | $-0.76 | $-0.84 | $-0.89 | |
| Shares (Basic) | 83,747,104 | 82,050,618 | · | 73,396,435 | 72,466,203 | 71,969,411 | · | 64,627,847 | 58,558,145 | 58,371,480 | · | 56,782,379 | 48,500,516 | 42,354,520 | |
| Shares (Diluted) | 83,747,104 | 82,050,618 | · | 73,396,435 | 72,466,203 | 71,969,411 | · | 64,627,847 | 58,558,145 | 58,371,480 | · | 56,782,379 | 48,500,516 | 42,354,520 | |
| EBITDA | $-4M | $-15M | · | $-15M | $-60M | $-79M | · | $-71M | $-77M | $-70M | · | $-36M | $-32M | $-30M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $181M | $130M | $135M | $150M | $212M | $297M | $335M | $276M | $322M | $381M | $214M | $249M | $130M | |
| Receivables | $97M | $81M | $78M | $56M | $51M | $36M | $39M | $21M | $11M | $4M | $2M | · | · | · | |
| Inventory | $8M | $7M | $6M | $4M | $3M | $3M | $3M | $3M | $2M | $1M | $1M | $111.0K | $111.0K | · | |
| Prepaid Expense | $8M | $8M | $15M | $13M | $15M | $13M | $21M | $15M | $15M | $13M | $13M | $13M | $9M | $10M | |
| Current Assets | $296M | $277M | $229M | $208M | $219M | $265M | $360M | $374M | $305M | $340M | $397M | $227M | $258M | $140M | |
| PP&E (Net) | $971.0K | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| PP&E (Gross) | · | · | $5M | · | · | · | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | |
| Accum. Depreciation | · | · | $3M | · | · | · | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Other Non-current Assets | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $299.0K | |
| Total Assets | $327M | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M | $356M | $414M | $237M | $265M | $144M | |
| Accounts Payable | $5M | $6M | $5M | $1M | $4M | $12M | $11M | $7M | $8M | $8M | $13M | $6M | $4M | $5M | |
| Accrued Liabilities | $109M | $83M | $90M | $65M | $64M | $43M | $53M | $36M | $27M | $17M | $17M | $13M | $15M | $8M | |
| Current Liabilities | $154M | $125M | $132M | $93M | $92M | $74M | $86M | $65M | $47M | $43M | $39M | $24M | $22M | $14M | |
| Capital Leases | $2M | $2M | $2M | $2M | $589.0K | $0 | · | $0 | $133.0K | $292.0K | $462.0K | $628.0K | $789.0K | $945.0K | |
| Other Non-current Liabilities | $4M | $4M | $4M | $12M | $12M | $12M | $12M | $11M | $10M | $10M | $10M | $8M | $8M | $8M | |
| Total Liabilities | $671M | $642M | $697M | $663M | $656M | $633M | $632M | $574M | $553M | $505M | $487M | $255M | $247M | $234M | |
| Long-term Debt | $165M | $164M | $209M | $207M | $205M | $203M | $201M | $176M | $174M | $149M | $138M | $99M | $98M | $97M | |
| Total Debt | $165M | $164M | · | $207M | $205M | $203M | · | $176M | $174M | $149M | · | $99M | $98M | $97M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | |
| Retained Earnings | $-1.53B | $-1.51B | $-1.48B | $-1.46B | $-1.43B | $-1.36B | $-1.26B | $-1.19B | $-1.10B | $-1.01B | $-929M | $-849M | $-806M | $-765M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Stockholders' Equity | $-344M | $-337M | $-438M | $-423M | $-406M | $-338M | $-254M | $-187M | $-234M | $-149M | $-73M | $-18M | $18M | $-90M | |
| Liabilities + Equity | $327M | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M | $356M | $414M | $237M | $265M | $144M | |
| Shares Outstanding | 80,070,048 | 79,442,367 | 71,419,025 | 71,043,149 | 70,104,419 | 69,638,070 | 68,518,238 | 68,323,938 | 58,601,025 | 58,524,101 | 57,970,044 | 56,809,085 | 56,639,085 | 43,571,140 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $114.0K | $110.0K | $128.0K | $156.0K | $172.0K | $177.0K | $193.0K | $191.0K | $197.0K | $214.0K | $185.0K | $121.0K | $123.0K | $146.0K | |
| Stock-based Comp | $7M | $6M | $6M | $9M | $8M | $6M | $7M | $6M | $6M | $6M | $25M | $6M | $7M | $7M | |
| Other Non-cash | · | $9M | · | · | · | $4M | · | · | · | $8M | · | · | · | $-9M | |
| Operating Cash Flow | $-2M | $-16M | $-5M | $-14M | $-63M | $-85M | $-63M | $-64M | $-71M | $-69M | $-44M | $-32M | $-22M | $-40M | |
| CapEx | $44.0K | $61.0K | $87.0K | $27.0K | $97.0K | $18.0K | $5.0K | $44.0K | $46.0K | $40.0K | $475.0K | $939.0K | $6.0K | $214.0K | |
| Investing Cash Flow | $-44.0K | $-61.0K | $-87.0K | $-27.0K | $-97.0K | $-18.0K | $-5.0K | $-44.0K | $-46.0K | $-40.0K | $-475.0K | $-939.0K | $-6.0K | $-214.0K | |
| Debt Issued | $0 | $173M | $0 | $0 | $0 | $0 | $25M | $0 | $25M | $10M | $39M | $0 | $0 | $0 | |
| Net Debt Issued | · | $-56M | · | · | · | $0 | · | · | · | $10M | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | |
| Financing Cash Flow | $4M | $67M | $-97.0K | $-271.0K | $80.0K | $0 | $26M | $122M | $25M | $10M | $212M | $13.0K | $142M | $14M | |
| Net Change in Cash | $2M | $51M | $-5M | $-14M | $-63M | $-85M | $-37M | $58M | $-46M | $-59M | $168M | $-33M | $119M | $-26M | |
| Free Cash Flow | · | $-16M | · | · | · | $-85M | · | · | · | $-69M | · | · | · | $-40M |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.7% | 79.4% | · | 87.5% | 87.2% | 86.9% | · | 85.6% | 81.2% | 77.7% | · | · | · | · | |
| Operating Margin | -5.3% | -26.6% | · | -30.9% | -151.7% | -276.5% | · | -433.0% | -1055.4% | -3658.7% | · | · | · | · | |
| Net Margin | -23.7% | -52.1% | · | -60.6% | -191.9% | -330.7% | · | -523.3% | -1248.6% | -4333.3% | · | · | · | · | |
| EBITDA Margin | -5.3% | -26.4% | · | -30.9% | -151.7% | -275.9% | · | -433.0% | -1055.4% | -3647.5% | · | · | · | · | |
| ROA | -6.1% | -10.1% | · | -9.6% | -26.6% | -29.0% | · | -27.4% | -31.3% | -33.1% | · | -19.7% | -17.1% | -25.8% | |
| ROE | 4.7% | 9.0% | · | 9.8% | 23.7% | 38.7% | · | 83.5% | 84.6% | 69.4% | · | 195.7% | -772.9% | 145.0% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.2 | · | 2.2 | 2.4 | 3.6 | · | 5.7 | 6.5 | 7.8 | · | 9.5 | 12.0 | 9.7 | |
| Quick Ratio | 1.8 | 2.1 | · | 2.1 | 2.2 | 3.4 | · | 5.4 | 6.1 | 7.5 | · | 8.9 | 11.6 | 9.0 | |
| Debt / Equity | -0.5 | -0.5 | · | -0.5 | -0.5 | -0.6 | · | -0.9 | -0.7 | -1.0 | · | -5.6 | 5.6 | -1.1 | |
| LT Debt / Equity | -0.5 | -0.5 | · | -0.5 | -0.5 | -0.6 | · | -0.9 | -0.7 | -1.0 | · | -5.6 | 5.6 | -1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -4.4 | -4.1 | · | -3.5 | -3.3 | -3.3 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | · | · | · | |
| Inventory Turnover | 2.7 | 2.5 | · | 1.8 | 1.8 | 1.6 | · | 1.5 | 1.2 | 0.6 | · | · | · | · | |
| Receivables Turnover | 1.0 | 1.0 | · | 1.3 | 1.3 | 1.4 | · | 1.6 | 1.3 | 1.0 | · | · | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.30 | $-4.24 | · | $-5.95 | $-5.79 | $-4.86 | · | $-2.74 | $-3.99 | $-2.54 | · | $-0.31 | $0.31 | $-2.07 | |
| Revenue / Share | $0.89 | $0.71 | · | $0.67 | $0.55 | $0.40 | · | $0.25 | $0.13 | $0.03 | · | · | · | · | |
| Cash Flow / Share | · | $-0.19 | · | · | · | $-1.18 | · | · | · | $-1.18 | · | · | · | $-0.94 | |
| Cash / Share | $2.28 | $2.28 | · | $1.90 | $2.13 | $3.05 | · | $4.90 | $4.71 | $5.51 | · | $3.76 | $4.39 | $2.97 | |
| EPS (TTM) | $-1.25 | $-2.09 | · | $-3.76 | $-4.67 | $-5.18 | · | $-5.74 | $-5.18 | $-4.46 | · | $-3.82 | $-4.38 | $-4.87 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $240M | $205M | · | $147M | $114M | $82M | · | $26M | $10M | $3M | · | · | · | · | |
| Net Income TTM | $-99M | $-157M | · | $-275M | $-330M | $-346M | · | $-339M | $-297M | $-247M | · | $-177M | $-185M | $-195M | |
| Market Cap | $869M | $883M | · | $836M | $672M | $437M | · | $1.24B | $604M | $622M | · | $589M | $811M | $311M | |
| Enterprise Value | $851M | $865M | · | $908M | $728M | $428M | · | $1.08B | $502M | $448M | · | $475M | $660M | $278M | |
| P/E | -8.7 | -5.3 | · | -3.1 | -2.1 | -1.2 | · | -3.1 | -2.0 | -2.4 | · | -2.7 | -3.3 | -1.5 | |
| P/S | 3.6 | 4.3 | · | 5.7 | 5.9 | 5.3 | · | 47.0 | 60.9 | 239.6 | · | · | · | · | |
| P/B | -2.5 | -2.6 | · | -2.0 | -1.7 | -1.3 | · | -6.6 | -2.6 | -4.2 | · | -33.1 | 46.1 | -3.4 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | · | 46.1 | · | |
| P / Cash Flow | · | -56.4 | · | · | · | -5.1 | · | · | · | -9.0 | · | · | · | -7.8 | |
| EV / Revenue | 3.6 | 4.2 | · | 6.2 | 6.4 | 5.2 | · | 41.0 | 50.6 | 172.8 | · | · | · | · | |
| Earnings Yield | -11.5% | -18.8% | · | -31.9% | -48.7% | -82.6% | · | -31.8% | -50.3% | -42.0% | · | -36.8% | -30.6% | -68.2% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $175M | $55M | $682.0K | $0 | · |
| Margen Bruto % | 87.1% | 85.6% | 75.5% | · | · |
| Margen Operativo % | -91.4% | -502.2% | -24532.5% | · | · |
| Beneficio neto | $-221M | $-334M | $-202M | $-198M | $-144M |
| EPS Diluido | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -0.5 | -0.8 | -1.9 | -1.3 | 1.2 |
| Ratio corriente | 1.7 | 4.2 | 10.2 | 6.1 | 9.9 |
| Ratio Rápido | 1.6 | 3.9 | 9.9 | 5.9 | 9.7 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-167M | $-267M | $-139M | $-148M | $-149M |
Propietarios institucionales (13F) 176 declarantes · $818.8M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
176
Valor en tenencia
$818.8M
Nuevas posiciones
26
Posiciones cerradas
31
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 26 (-13 vs trimestre anterior) | 31 (-4 vs trimestre anterior) | 59 (-16 vs trimestre anterior) | 52 (+12 vs trimestre anterior) | +5.7M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $135 261 406 | 12 466 489 | 16,52% | Acciones |
| Medicxi Ventures Management (Jersey) Ltd | $80 990 606 | 7 464 572 | 9,89% | Acciones |
| VANGUARD GROUP INC | $52 709 931 | 3 177 211 | 6,44% | Acciones |
| BlackRock, Inc. | $49 097 648 | 4 525 129 | 6,00% | Acciones |
| Invesco Ltd. | $43 722 581 | 4 029 731 | 5,34% | Acciones |
| Carlyle Group Inc. | $37 940 367 | 3 496 808 | 4,63% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $36 627 799 | 3 375 834 | 4,47% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $28 827 842 | 2 656 944 | 3,52% | Acciones |
| FRANKLIN RESOURCES INC | $21 383 482 | 1 970 828 | 2,61% | Acciones |
| NEA Management Company, LLC | $21 267 834 | 1 960 169 | 2,60% | Acciones |
| 683 Capital Management, LLC | $20 072 501 | 1 850 000 | 2,45% | Acciones |
| GOLDMAN SACHS GROUP INC | $19 291 647 | 1 778 032 | 2,36% | Acciones |
| STATE STREET CORP | $17 211 605 | 1 586 323 | 2,10% | Acciones |
| Catalys Pacific, LLC | $16 208 316 | 1 493 854 | 1,98% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $15 871 000 | 1 462 738 | 1,94% | Acciones |
| WASATCH ADVISORS LP | $14 897 577 | 1 340 916 | 1,82% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $14 277 589 | 1 315 687 | 1,74% | Acciones |
| Ensign Peak Advisors, Inc | $11 413 256 | 1 051 913 | 1,39% | Acciones |
| Propel Bio Management, LLC | $11 396 384 | 1 050 358 | 1,39% | Acciones |
| Point72 Asset Management, L.P. | $11 090 794 | 1 022 193 | 1,35% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $8 643 446 | 796 631 | 1,06% | Acciones |
| SummitTX Capital, L.P. | $8 566 618 | 789 550 | 1,05% | Acciones |
| HSBC HOLDINGS PLC | $7 701 936 | 709 695 | 0,94% | Acciones |
| MARSHALL WACE, LLP | $7 227 078 | 666 090 | 0,88% | Acciones |
| EcoR1 Capital, LLC | $6 781 250 | 625 000 | 0,83% | Acciones |
| PERCEPTIVE ADVISORS LLC | $5 772 200 | 532 000 | 0,70% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $5 631 975 | 519 076 | 0,69% | Acciones |
| CITADEL ADVISORS LLC | $5 216 680 | 480 800 | 0,64% | Opción de compra |
| NORTHERN TRUST CORP | $4 972 565 | 458 301 | 0,61% | Acciones |
| StepStone Group LP | $4 689 364 | 422 085 | 0,57% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4 547 170 | 419 094 | 0,56% | Acciones |
| Woodline Partners LP | $4 004 214 | 369 052 | 0,49% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $3 847 117 | 354 573 | 0,47% | Acciones |
| AMERIPRISE FINANCIAL INC | $3 189 673 | 293 979 | 0,39% | Acciones |
| JPMORGAN CHASE & CO | $2 991 978 | 275 251 | 0,37% | Acciones |
| Simplify Asset Management Inc. | $2 704 547 | 249 267 | 0,33% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $2 456 440 | 226 400 | 0,30% | Acciones |
| JANE STREET GROUP, LLC | $2 307 860 | 212 706 | 0,28% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2 281 755 | 210 300 | 0,28% | Opción de compra |
| UBS Group AG | $2 219 618 | 204 573 | 0,27% | Acciones |
| NewEdge Advisors, LLC | $2 212 988 | 203 962 | 0,27% | Acciones |
| Avidity Partners Management LP | $2 170 000 | 200 000 | 0,27% | Acciones |
| MORGAN STANLEY | $2 169 013 | 199 909 | 0,26% | Acciones |
| Jump Financial, LLC | $2 081 746 | 191 866 | 0,25% | Acciones |
| Opaleye Management Inc. | $2 013 641 | 185 589 | 0,25% | Acciones |
| CITADEL ADVISORS LLC | $2 006 176 | 184 901 | 0,25% | Acciones |
| Trexquant Investment LP | $1 886 641 | 173 884 | 0,23% | Acciones |
| Jones Hill Capital LP | $1 752 123 | 161 486 | 0,21% | Acciones |
| Bank of New York Mellon Corp | $1 652 595 | 152 313 | 0,20% | Acciones |
| WELLS FARGO & COMPANY/MN | $1 649 221 | 152 002 | 0,20% | Acciones |
Activistas y propietarios del %+ 5 5 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences XII, L.P., FHMLS XII, L.P., FHMLS XII, L.L.C., James N. Topper, Patrick J. Heron ×3 presentaciones | 4 de noviembre de 2025 | 8,60% | Enmienda | · | SEC |
| Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., James N. Topper, Patrick J. Heron, Albert Cha, James Brush, Daniel Estes ×8 presentaciones | 22 de agosto de 2024 | · | Presentación inicial | Inversión pasiva | SEC |
| Takeda Pharmaceutical Company Limited ×3 presentaciones | 10 de abril de 2024 | · | Presentación inicial | · | SEC |
| Frazier Life Sciences IX, L.P ., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., James N. Topper, Patrick J. Heron, Albert Cha, James Brush, Daniel Estes | 26 de mayo de 2023 | · | Presentación inicial | Inversión pasiva | SEC |
| S.S. OR ×5 presentaciones | 12 de noviembre de 2021 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 20 insiders · 9 directivos · 12 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Steven L Basta | President and CEO | 10 de febrero de 2026 F | 373 315 | 0 | 0 | $0 |
| Molly Henderson | CFO and CBO | 7 de abril de 2025 S | 89 868 | 0 | 0 | $0 |
| Todd P. Branning | Chief Financial Officer | 28 de enero de 2021 A | · | 0 | 0 | $0 |
| Terrie Curran | President and Chief Executive | 27 de febrero de 2025 A | 360 465 | 0 | 0 | $0 |
| Azmi Nabulsi | Chief Operating Officer | 27 de febrero de 2025 A | 312 590 | 0 | 0 | $0 |
| Robert Charles Breedlove | Principal Accounting Officer | 3 de septiembre de 2026 F | 59 465 | 0 | 1 | $-7 079 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | 10 de febrero de 2026 F | 88 660 | 0 | 0 | $0 |
| Sanjeev Narula | Chief Financial & Bus. Officer | 2 de enero de 2026 A | 226 715 | 0 | 0 | $0 |
| Anthony J. Guzzo | VP, Chief Accounting Officer | 19 de enero de 2022 A | 8 399 | 0 | 0 | $0 |
| Asit Parikh | Consejero | 22 de mayo de 2026 G | 148 500 | 0 | 0 | $0 |
| Mark Stenhouse | Consejero | 19 de mayo de 2026 A | 54 122 | 0 | 0 | $0 |
| Theodore R Schroeder | Consejero | 19 de mayo de 2026 A | 45 122 | 0 | 0 | $0 |
| James N. Topper | Consejero | 19 de mayo de 2026 A | 66 718 | 0 | 0 | $0 |
| Frank Karbe | Consejero | 19 de mayo de 2026 A | 91 622 | 0 | 0 | $0 |
| Michael F Cola | Consejero | 19 de mayo de 2026 A | 63 920 | 0 | 0 | $0 |
| Heidi Kunz | Consejero | 19 de mayo de 2026 A | 54 122 | 0 | 0 | $0 |
| David A Socks | Consejero | 23 de mayo de 2024 A | 19 500 | 0 | 0 | $0 |
| Tadataka Yamada | Consejero | 21 de mayo de 2021 A | · | 0 | 0 | $0 |
| Jonathan S. Edwards | Consejero | 29 de octubre de 2019 C | 47 984 | 0 | 0 | $0 |
| Takeda Pharmaceutical Company Limited | · | 24 de enero de 2024 S | 3 755 583 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 24 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,16% | 130 873 NS | 31 de julio de 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0,64% | 15 083 NS | 31 de julio de 2026 | N-PORT |
| IWC · iShares Trust | 0,10% | 167 720 SH | 11 de septiembre de 2026 | Diario |
| IHE · iShares Trust | 0,10% | 187 890 SH | 11 de septiembre de 2026 | Diario |
| VFMO · VANGUARD WELLINGTON FUND | 0,04% | 78 352 SH | 19 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,04% | 5 742 SH | 2 de octubre de 2026 | Diario |
| IBB · iShares Trust | 0,04% | 439 273 SH | 11 de septiembre de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 283 184 SH | 19 de agosto de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 30 521 SH | 19 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,02% | 18 633 SH | 11 de septiembre de 2026 | Diario |
| RSSL · Global X Funds | 0,01% | 23 493 NS | 31 de julio de 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1 255 887 SH | 11 de septiembre de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 586 438 SH | 19 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 15 003 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,01% | 148 237 SH | 19 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,01% | 132 821 SH | 11 de septiembre de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 22 619 NS | 31 de julio de 2026 | N-PORT |
| WSML · iShares Trust | 0,00% | 2 597 SH | 11 de septiembre de 2026 | Diario |
| ITOT · iShares Trust | 0,00% | 79 252 SH | 11 de septiembre de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 9 388 SH | 3 de septiembre de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2 007 668 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3 478 SH | 19 de agosto de 2026 | Diario |
| IWN · iShares Trust | · | 330 692 SH | 11 de septiembre de 2026 | Diario |
| ISCB · iShares Trust | · | 2 641 SH | 11 de septiembre de 2026 | Diario |
PHAT Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 17 analistas
COMPRA
Objetivo mediano
$21.00
+203,5%
6 35,3%
Compra fuerte
9 52,9%
Compra
2 11,8%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
11 analistas · 2026-09-29Objetivo medio $20.45 +195,6%
← Por Debajo de Todos los Objetivos
Precio Actual $6.92
Mín$10.00
Media$20.45
Máx$29.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| CRMD | $922M | 5.7 | 617.0% | 52.3% | 52.1% | 88.5% |
| CTNM | · | -5.3 | · | · | -27.7% | · |
| ARVN | $753M | -10.4 | -0.30% | -30.8% | -15.5% | · |
| EOLS | $432M | -8.3 | 11.6% | -17.4% | 247.3% | 66.3% |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Jul 30, 2026